Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 113.3%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totaling 441,157 shares, a growth of 113.3% from the June 15th total of 206,873 shares. Approximately 7.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 302,873 shares, the days-to-cover ratio is presently 1.5 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Armata Pharmaceuticals to a “hold” rating in a report on Monday, May 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Trading Down 5.8%

ARMP traded down $0.23 on Thursday, hitting $3.76. 342,670 shares of the stock were exchanged, compared to its average volume of 219,490. Armata Pharmaceuticals has a 12 month low of $2.32 and a 12 month high of $16.34. The business has a 50-day moving average of $7.01 and a two-hundred day moving average of $8.36.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its earnings results on Wednesday, May 13th. The company reported ($3.16) EPS for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The business had revenue of $0.79 million for the quarter, compared to analysts’ expectations of $0.74 million. Analysts predict that Armata Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ARMP. Madison Asset Management LLC bought a new stake in Armata Pharmaceuticals during the first quarter worth $21,583,000. 683 Capital Management LLC bought a new stake in shares of Armata Pharmaceuticals during the 4th quarter worth $878,000. Geode Capital Management LLC boosted its stake in Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after buying an additional 5,342 shares in the last quarter. Sei Investments Co. acquired a new stake in Armata Pharmaceuticals in the first quarter valued at about $760,000. Finally, Renaissance Technologies LLC grew its position in Armata Pharmaceuticals by 65.9% in the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after acquiring an additional 27,200 shares during the last quarter. 3.57% of the stock is owned by institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.